Please join us in welcoming Dr Yu Yu to the Curtin Health Innovation Research Institute.

Dr Yu Yu graduated in Medical Science (Pharmacology and Biochemistry) from the University of Sydney.  She was trained in anti-cancer therapeutics development in the Molecular Pharmacology and Pathology laboratory at the same institution, where she gained a PhD in Medicine. Her postdoctoral training has been conducted in TeLinde Gynecologic Pathology Laboratory at Johns Hopkins University School of Medicine (United States), under the guidance of Professors Ie-Ming Shih and Tian-Li Wang, with the focus on ovarian cancer therapy.

Yu Yu’s primary research goals are dedicated to combat cancer and its recurrence.  A report from this work was published in Cancer Cell, titled “Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules” Cancer Cell 28(1):82-96. She has a keen research interest in experimental therapeutics, with experiences in drug classes that target cellular iron, cytoskeletal dynamics and kinase activities. Some of her studies include investigation on the “omics” mechanism of chemotherapy resistance, orthotopic animal models for recurrent tumors, preclinical research on investigational new drugs and biomarkers to improve pharmacological response, and rational combinatorial therapy for improved patient survival.